Julien Mazières, European Society for Medical Oncology (IMAGE)

European Society for Medical Oncology

Julien Mazières, European Society for Medical Oncology

Caption

During the European Lung Cancer Congress 2018, Prof. Mazières presents the three-year survival results of the randomised phase 2 POPLAR trial in second line, which is the longest follow-up reported to date with anti-programmed death ligand 1 (PD-L1) immunotherapy in patients with previously treated, advanced non-small-cell lung cancer (NSCLC)

Credit

© ELCC 2018

Usage Restrictions

This picture may only be used with appropriate caption or credit

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.